+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Lung Cancer Therapeutics Market - Global Forecast 2026-2032- Product Image
Lung Cancer Therapeutics Market - Global Forecast 2026-2032- Product Image
Sale

Lung Cancer Therapeutics Market - Global Forecast 2026-2032

  • Report

  • 183 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4904951
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Lung Cancer Therapeutics Market is projected to reach USD 36.07 Billion in 2026. It is expected to continue growing at a CAGR of 8.77%, reaching USD 59.89 Billion by 2032.

Lung cancer therapeutics are being reshaped by precision oncology, immuno-oncology, antibody-drug conjugates, radioligand and bispecific approaches, and earlier molecular testing across non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). According to global cancer surveillance data, lung cancer remains one of the most frequently diagnosed cancers worldwide and the leading cause of cancer mortality, reinforcing the urgency for therapies that improve survival while reducing toxicity.

The market is increasingly defined by biomarker-directed treatment for EGFR, ALK, ROS1, BRAF, MET, RET, NTRK, HER2, and KRAS G12C alterations, alongside PD-1, PD-L1, and CTLA-4 immune checkpoint inhibitors. As treatment algorithms move from late-stage disease into adjuvant, neoadjuvant, and perioperative settings, commercial opportunity is expanding beyond drug launch performance to include companion diagnostics, real-world evidence, access strategy, adherence support, and sequencing intelligence.

Transformative Shifts in the Lung Cancer Therapeutics Landscape

The lung cancer treatment landscape has shifted from broad chemotherapy regimens toward personalized, biomarker-led care. Comprehensive genomic profiling is now central to NSCLC management, while liquid biopsy is improving testing access when tissue is limited or repeat biopsy is impractical. These changes are accelerating earlier identification of actionable mutations and enabling more precise therapy selection across metastatic and earlier-stage disease.

Transformative shifts also include immunotherapy combinations, next-generation tyrosine kinase inhibitors, bispecific antibodies, and antibody-drug conjugates designed to address resistance, improve intracranial activity, and extend durable response. In SCLC, where progress has historically been slower, chemo-immunotherapy, DLL3-directed approaches, PARP pathway research, and novel maintenance strategies are creating renewed clinical and commercial momentum.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative force across lung cancer therapeutics, improving discovery, trial design, diagnostics, and treatment monitoring. AI-enabled imaging tools support earlier nodule detection and risk stratification, while computational biology helps identify drug targets, resistance mechanisms, and patient subgroups most likely to respond to targeted therapy, immunotherapy, or combination regimens.

In clinical development, AI is improving site selection, eligibility matching, protocol feasibility, synthetic control design, pharmacovigilance, and real-world evidence generation. For commercial and medical affairs teams, machine learning can help map testing gaps, therapy sequencing, adherence risks, referral leakage, and regional access barriers. The strongest near-term value will come from governed AI systems integrated with validated clinical data, pathology workflows, imaging repositories, privacy safeguards, and regulatory-grade evidence standards.

Key Regional Insights Across Major Lung Cancer Therapeutics Markets

North America remains a leading region for lung cancer therapeutics due to high biomarker testing adoption, advanced oncology infrastructure, rapid uptake of approved targeted therapies and immunotherapies, and strong participation in clinical trials. Europe continues to expand precision oncology through national cancer plans, health technology assessment frameworks, screening programs, and cross-border research networks, although reimbursement timelines and molecular testing access can vary across countries.

Asia-Pacific is one of the most strategically important regions because of its high disease burden, large patient populations, and elevated prevalence of EGFR-mutated NSCLC in several East Asian populations. Latin America is improving access to immunotherapy and molecular diagnostics, but affordability, referral pathways, and testing infrastructure remain uneven between public and private systems. The Middle East is investing in oncology centers, genomic medicine, and specialist cancer care, particularly in GCC markets, while Africa faces the greatest access challenges, including late diagnosis, limited pathology and radiotherapy capacity, fragmented cancer registries, and constrained reimbursement for innovative lung cancer drugs.

Key Group Insights for Lung Cancer Therapeutics Strategy

The G7 continues to influence global lung cancer therapeutics through innovation funding, regulatory leadership, premium oncology reimbursement, and extensive clinical trial networks. The European Union is central to harmonized regulatory pathways, cancer screening initiatives, joint evidence generation, and cross-country oncology policy alignment, while NATO countries collectively represent a large base of advanced oncology infrastructure, academic research centers, and pharmaceutical demand.

BRICS markets are increasingly important because China, India, Brazil, Russia, and South Africa combine large patient pools, expanding domestic pharmaceutical capabilities, and rising use of targeted therapy where diagnostics and reimbursement are available. ASEAN countries are improving oncology capacity, but access differs substantially between Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the Philippines due to variation in insurance coverage, pathology capacity, and specialist availability. GCC markets are prioritizing specialty care investment, genomic testing, public-sector modernization, and medical tourism, creating opportunities for premium lung cancer therapeutics when clinical evidence, reimbursement, and local partnerships align.

Key Country Insights in Lung Cancer Therapeutics

The United States is a highly influential market for lung cancer therapeutics, supported by regulatory innovation pathways, broad clinical trial activity, guideline-driven biomarker testing, and strong adoption of targeted therapy and immunotherapy. Canada follows evidence-based reimbursement processes and pan-Canadian oncology assessment practices, while Mexico and Brazil are expanding oncology access amid budget constraints and variability between public and private systems. The United Kingdom, Germany, France, Italy, and Spain remain critical European markets shaped by national HTA decisions, cancer care pathways, screening priorities, and molecular testing programs, while Russia faces access variability linked to health system funding, regional disparities, and geopolitical pressures.

China is a major growth engine due to high lung cancer incidence, domestic innovation, faster regulatory review for priority therapies, and rapid expansion of targeted therapy and immunotherapy. Japan and South Korea are mature precision oncology markets with strong diagnostics capability, active clinical research, and high relevance for EGFR-directed treatment. India offers significant long-term potential due to a large patient base and rising oncology investment, but requires affordability-focused strategies, broader molecular testing access, and cancer infrastructure expansion. Australia benefits from advanced cancer care, public reimbursement mechanisms, organized clinical trial networks, and active participation in global lung cancer research.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize biomarker access as a growth enabler, not only a clinical requirement. Partnerships with pathology networks, liquid biopsy providers, hospitals, oncology societies, and payers can reduce missed testing opportunities and support appropriate use of targeted therapies and immunotherapies across NSCLC and selected SCLC settings.

Organizations should also build evidence strategies that demonstrate survival benefit, quality-of-life impact, sequencing value, safety management, and budget relevance. Successful commercialization will require differentiated positioning in crowded PD-1/PD-L1 and TKI segments, investment in resistance-management pipelines, trial designs that reflect biomarker-defined populations, equitable access models in emerging markets, and compliant AI tools that improve trial execution and real-world decision support.

Research Methodology

This executive summary is based on secondary research and analytical synthesis of publicly available, evidence-based sources, including global cancer epidemiology data, regulatory approvals, clinical practice guidelines, peer-reviewed oncology literature, clinical trial registries, health technology assessment trends, reimbursement policy updates, and cancer control publications.

The methodology emphasizes triangulation across disease burden, treatment standards, biomarker prevalence, regulatory activity, reimbursement environment, diagnostic infrastructure, and regional access conditions. Insights were evaluated for relevance to lung cancer therapeutics, including NSCLC, SCLC, targeted therapies, immunotherapies, antibody-drug conjugates, companion diagnostics, liquid biopsy, resistance mechanisms, real-world evidence, and AI-enabled oncology applications.

Conclusion

Lung cancer therapeutics are entering a more precise, data-intensive, and competitive era. The strongest market participants will be those that connect innovative medicines with diagnostic readiness, payer-relevant evidence, AI-enabled operational efficiency, and practical access strategies across developed and emerging healthcare systems.

As treatment moves earlier in the disease course and resistance mechanisms become central to pipeline planning, durable advantage will depend on integrated oncology ecosystems. Organizations that combine scientific differentiation with regional execution discipline, equitable testing access, and evidence-based sequencing strategies are best positioned to improve outcomes and capture growth in the global lung cancer therapeutics market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Lung Cancer Therapeutics Market, by Therapy Type
7.1. Introduction
7.2. Chemotherapy
7.2.1. Alkylating Agents
7.2.2. Platinum-Based
7.2.3. Taxanes
7.2.4. Topoisomerase Inhibitors
7.3. Immunotherapy
7.3.1. CTLA-4 Inhibitors
7.3.2. PD-1 Inhibitors
7.3.3. PD-L1 Inhibitors
7.4. Radiation Therapy
7.4.1. Brachytherapy
7.4.2. External Beam Radiation
7.4.3. Stereotactic Body Radiation
7.5. Supportive Care
7.5.1. Antiemetics
7.5.2. Bone-Modifying Agents
7.5.3. Hematopoietic Growth Factors
7.6. Surgery
7.7. Targeted Therapy
7.7.1. Anaplastic Lymphoma Kinase (ALK) Inhibitors
7.7.2. BRAF Inhibitors
7.7.3. EGFR Inhibitors
8. Lung Cancer Therapeutics Market, by Mode Of Administration
8.1. Introduction
8.2. Inhalation
8.3. Injectable
8.4. Oral
9. Lung Cancer Therapeutics Market, by Line Of Therapy
9.1. Introduction
9.2. First-Line
9.3. Second-Line
9.4. Third-Line & Beyond
10. Lung Cancer Therapeutics Market, by Disease Stage
10.1. Introduction
10.2. Stage I
10.3. Stage II
10.4. Stage III
10.5. Stage IV
11. Lung Cancer Therapeutics Market, by Prescription Status
11.1. Introduction
11.2. Branded
11.3. Generic
12. Lung Cancer Therapeutics Market, by Distribution Channel
12.1. Introduction
12.2. Offline Retail
12.3. Online Retail
13. Lung Cancer Therapeutics Market, by Cancer Type
13.1. Introduction
13.2. Non-Small Cell Lung Cancer (NSCLC)
13.2.1. Adenocarcinoma
13.2.2. Large Cell Carcinoma
13.2.3. Squamous Cell Carcinoma
13.3. Small Cell Lung Cancer (SCLC)
14. Lung Cancer Therapeutics Market, by End User
14.1. Introduction
14.2. Ambulatory Infusion Centers
14.3. Cancer Centers
14.4. Homecare Settings
14.5. Hospitals
15. Lung Cancer Therapeutics Market, by Region
15.1. Europe
15.2. Asia-Pacific
15.3. North America
15.4. Latin America
15.5. Middle East
15.6. Africa
16. Lung Cancer Therapeutics Market, by Group
16.1. NATO
16.2. G7
16.3. European Union
16.4. BRICS
16.5. ASEAN
16.6. GCC
17. Lung Cancer Therapeutics Market, by Country
17.1. United States
17.2. China
17.3. Germany
17.4. Japan
17.5. India
17.6. United Kingdom
17.7. France
17.8. Canada
17.9. Australia
17.10. Spain
17.11. Italy
17.12. South Korea
17.13. Brazil
17.14. Russia
17.15. Mexico
18. Competitive Landscape
18.1. Market Share Analysis, 2025
18.2. FPNV Positioning Matrix, 2025
18.3. Market Concentration Analysis, 2025
18.3.1. Concentration Ratio (CR)
18.3.2. Herfindahl Hirschman Index (HHI)
18.4. Recent Developments & Impact Analysis, 2025
18.5. Product Portfolio Analysis, 2025
18.6. Benchmarking Analysis, 2025
19. Company Profiles
19.1. AstraZeneca PLC
19.2. Merck & Co., Inc.
19.3. F. Hoffmann-La Roche Ltd
19.4. Bristol-Myers Squibb Company
19.5. Regeneron Pharmaceuticals Inc.
19.6. Novartis AG
19.7. Daiichi Sankyo, Inc.
19.8. Pfizer Inc.
19.9. Eli Lilly and Company
19.10. Johnson & Johnson Services, Inc.
19.11. Amgen Inc.
19.12. Takeda Pharmaceutical Company Limited
19.13. GlaxoSmithKline plc
19.14. AbbVie Inc.
19.15. Astellas Pharma Inc.
19.16. Bayer AG
19.17. Boehringer Ingelheim International GmbH
19.18. Candel Therapeutics, Inc.
19.19. Cullinan Therapeutics, Inc.
19.20. Dr. Reddy’s Laboratories Ltd.
19.21. Fresenius Kabi AG
19.22. Innovent Biologics (Suzhou) Co., Ltd.
19.23. Jazz Pharmaceuticals, Inc.
19.24. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
19.25. MAIA Biotechnology, Inc.
19.26. Nuvalent, Inc.
19.27. OS Therapies Inc.
19.28. Sanofi S.A
19.29. Shanghai Henlius Biotech, Inc.
19.30. Summit Therapeutics Inc.
19.31. Teva Pharmaceutical Industries Ltd.
19.32. Viatris Inc.
List of Figures
FIGURE 1. GLOBAL LUNG CANCER THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL LUNG CANCER THERAPEUTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL LUNG CANCER THERAPEUTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL LUNG CANCER THERAPEUTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2025 VS 2032 (%)
FIGURE 13. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2025 VS 2032 (%)
FIGURE 15. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 17. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2025 VS 2032 (%)
FIGURE 19. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 21. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 23. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 25. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 27. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. GLOBAL LUNG CANCER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 29. GLOBAL LUNG CANCER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL LUNG CANCER THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL CHEMOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL CHEMOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL ALKYLATING AGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL ALKYLATING AGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL ALKYLATING AGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL PLATINUM-BASED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL PLATINUM-BASED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL PLATINUM-BASED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL TAXANES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL TAXANES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL TAXANES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL TOPOISOMERASE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL TOPOISOMERASE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL TOPOISOMERASE INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL CTLA-4 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL CTLA-4 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL CTLA-4 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL PD-1 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL PD-1 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL PD-1 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL PD-L1 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL RADIATION THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL RADIATION THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL RADIATION THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL BRACHYTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL BRACHYTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL BRACHYTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL EXTERNAL BEAM RADIATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL EXTERNAL BEAM RADIATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL EXTERNAL BEAM RADIATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL STEREOTACTIC BODY RADIATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL STEREOTACTIC BODY RADIATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL STEREOTACTIC BODY RADIATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL SUPPORTIVE CARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL SUPPORTIVE CARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL SUPPORTIVE CARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL ANTIEMETICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL ANTIEMETICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL ANTIEMETICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL BONE-MODIFYING AGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL BONE-MODIFYING AGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL BONE-MODIFYING AGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL HEMATOPOIETIC GROWTH FACTORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL HEMATOPOIETIC GROWTH FACTORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL HEMATOPOIETIC GROWTH FACTORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL SURGERY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL SURGERY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL SURGERY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL BRAF INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL BRAF INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL EGFR INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL EGFR INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL EGFR INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL INHALATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL INHALATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL INHALATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL FIRST-LINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL FIRST-LINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL FIRST-LINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL SECOND-LINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL SECOND-LINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL SECOND-LINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL THIRD-LINE & BEYOND MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL THIRD-LINE & BEYOND MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL THIRD-LINE & BEYOND MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL STAGE I MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL STAGE I MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL STAGE I MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL STAGE II MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL STAGE II MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL STAGE II MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL STAGE III MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL STAGE III MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL STAGE III MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL STAGE IV MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL STAGE IV MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL STAGE IV MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL BRANDED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL BRANDED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL BRANDED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL GENERIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL GENERIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL GENERIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL OFFLINE RETAIL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL OFFLINE RETAIL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL OFFLINE RETAIL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL ONLINE RETAIL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL ONLINE RETAIL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL ONLINE RETAIL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL NON-SMALL CELL LUNG CANCER (NSCLC) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL NON-SMALL CELL LUNG CANCER (NSCLC) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL NON-SMALL CELL LUNG CANCER (NSCLC) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL ADENOCARCINOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL ADENOCARCINOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL ADENOCARCINOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL LARGE CELL CARCINOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL LARGE CELL CARCINOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL LARGE CELL CARCINOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL SQUAMOUS CELL CARCINOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL SQUAMOUS CELL CARCINOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 129. GLOBAL SQUAMOUS CELL CARCINOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 130. GLOBAL SMALL CELL LUNG CANCER (SCLC) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 131. GLOBAL SMALL CELL LUNG CANCER (SCLC) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 132. GLOBAL SMALL CELL LUNG CANCER (SCLC) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 133. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 134. GLOBAL AMBULATORY INFUSION CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 135. GLOBAL AMBULATORY INFUSION CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 136. GLOBAL AMBULATORY INFUSION CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 137. GLOBAL CANCER CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 138. GLOBAL CANCER CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 139. GLOBAL CANCER CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 140. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 141. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 142. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 143. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 144. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 145. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 146. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 147. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 148. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 149. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 150. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 151. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2017-2032 (USD MILLION)
TABLE 152. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2017-2032 (USD MILLION)
TABLE 153. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 154. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 155. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 156. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 157. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 158. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 159. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 160. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2017-2032 (USD MILLION)
TABLE 161. EUROPE LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 162. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 163. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 164. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 165. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 166. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2017-2032 (USD MILLION)
TABLE 167. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2017-2032 (USD MILLION)
TABLE 168. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 169. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 170. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 171. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 172. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 173. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 174. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 175. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2017-2032 (USD MILLION)
TABLE 176. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 177. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 178. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 179. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 180. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 181. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2017-2032 (USD MILLION)
TABLE 182. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2017-2032 (USD MILLION)
TABLE 183. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 184. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 185. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 186. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 187. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 188. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 189. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 190. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2017-2032 (USD MILLION)
TABLE 191. NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 192. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 193. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 194. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 195. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 196. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2017-2032 (USD MILLION)
TABLE 197. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2017-2032 (USD MILLION)
TABLE 198. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 199. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 200. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 201. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 202. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 203. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 204. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 205. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2017-2032 (USD MILLION)
TABLE 206. LATIN AMERICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 207. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 208. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 209. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 210. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 211. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2017-2032 (USD MILLION)
TABLE 212. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2017-2032 (USD MILLION)
TABLE 213. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 214. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 215. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 216. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 217. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 218. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 219. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 220. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2017-2032 (USD MILLION)
TABLE 221. MIDDLE EAST LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 222. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 223. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 224. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 225. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 226. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2017-2032 (USD MILLION)
TABLE 227. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2017-2032 (USD MILLION)
TABLE 228. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 229. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 230. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 231. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 232. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 233. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 234. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 235. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2017-2032 (USD MILLION)
TABLE 236. AFRICA LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 237. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 238. NATO LUNG CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 239. NATO LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 240. NATO LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 241. NATO LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 242. NATO LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2017-2032 (USD MILLION)
TABLE 243. NATO LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2017-2032 (USD MILLION)
TABLE 244. NATO LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 245. NATO LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 246. NATO LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 247. NATO LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 248. NATO LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 249. NATO LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 250. NATO LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 251. NATO LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2017-2032 (USD MILLION)
TABLE 252. NATO LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 253. G7 LUNG CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 254. G7 LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 255. G7 LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 256. G7 LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 257. G7 LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2017-2032 (USD MILLION)
TABLE 258. G7 LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2017-2032 (USD MILLION)
TABLE 259. G7 LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 260. G7 LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 261. G7 LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 262. G7 LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 263. G7 LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 264. G7 LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 265. G7 LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 266. G7 LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2017-2032 (USD MILLION)
TABLE 267. G7 LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 268. EUROPEAN UNION LUNG CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 269. EUROPEAN UNION LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 270. EUROPEAN UNION LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 271. EUROPEAN UNION LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 272. EUROPEAN UNION LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2017-2032 (USD MILLION)
TABLE 273. EUROPEAN UNION LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2017-2032 (USD MILLION)
TABLE 274. EUROPEAN UNION LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 275. EUROPEAN UNION LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 276. EUROPEAN UNION LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 277. EUROPEAN UNION LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 278. EUROPEAN UNION LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 279. EUROPEAN UNION LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 280. EUROPEAN UNION LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 281. EUROPEAN UNION LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2017-2032 (USD MILLION)
TABLE 282. EUROPEAN UNION LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 283. BRICS LUNG CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 284. BRICS LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 285. BRICS LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 286. BRICS LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 287. BRICS LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2017-2032 (USD MILLION)
TABLE 288. BRICS LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2017-2032 (USD MILLION)
TABLE 289. BRICS LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 290. BRICS LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 291. BRICS LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 292. BRICS LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 293. BRICS LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 294. BRICS LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 295. BRICS LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 296. BRICS LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2017-2032 (USD MILLION)
TABLE 297. BRICS LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 298. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 299. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 300. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 301. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 302. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2017-2032 (USD MILLION)
TABLE 303. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2017-2032 (USD MILLION)
TABLE 304. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 305. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 306. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 307. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 308. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 309. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 310. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 311. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2017-2032 (USD MILLION)
TABLE 312. ASEAN LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 313. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 314. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 315. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 316. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 317. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2017-2032 (USD MILLION)
TABLE 318. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2017-2032 (USD MILLION)
TABLE 319. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 320. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 321. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 322. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 323. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 324. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 325. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 326. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2017-2032 (USD MILLION)
TABLE 327. GCC LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 328. GLOBAL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 329. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 330. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 331. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 332. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 333. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2017-2032 (USD MILLION)
TABLE 334. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUPPORTIVE CARE, 2017-2032 (USD MILLION)
TABLE 335. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 336. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 337. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 338. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2017-2032 (USD MILLION)
TABLE 339. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 340. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 341. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
TABLE 342. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER (NSCLC), 2017-2032 (USD MILLION)
TABLE 343. UNITED STATES LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 344. CHINA LUNG CANCER THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 345. CHINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 346. CHINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2017-2032 (USD MILLION)
TABLE 347. CHINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
TABLE 348. CHINA LUNG CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2017

Companies Mentioned

  • AstraZeneca PLC
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd
  • Bristol-Myers Squibb Company
  • Regeneron Pharmaceuticals Inc.
  • Novartis AG
  • Daiichi Sankyo, Inc.
  • Pfizer Inc.
  • Eli Lilly and Company
  • Johnson & Johnson Services, Inc.
  • Amgen Inc.
  • Takeda Pharmaceutical Company Limited
  • GlaxoSmithKline plc
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Candel Therapeutics, Inc.
  • Cullinan Therapeutics, Inc.
  • Dr. Reddy’s Laboratories Ltd.
  • Fresenius Kabi AG
  • Innovent Biologics (Suzhou) Co., Ltd.
  • Jazz Pharmaceuticals, Inc.
  • Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • MAIA Biotechnology, Inc.
  • Nuvalent, Inc.
  • OS Therapies Inc.
  • Sanofi S.A
  • Shanghai Henlius Biotech, Inc.
  • Summit Therapeutics Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

Table Information

Report AttributeDetails
No. of Pages183
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 36.07 Billion
Forecasted Market Value ( USD ) by 2032 $ 59.89 Billion
Compound Annual Growth Rate8.7%
Regions CoveredGlobal
No. of Companies Mentioned32

Related Topics

Related Reports

Lung Cancer Drugs Market - Global Forecast 2026-2032 - Product Image

Lung Cancer Drugs Market - Global Forecast 2026-2032

  • Report
  • 199 Pages
  • Global
From
Immune Checkpoint Inhibitors for Lung Cancer Market - Global Forecast 2026-2032 - Product Image

Immune Checkpoint Inhibitors for Lung Cancer Market - Global Forecast 2026-2032

  • Report
  • 187 Pages
  • Global
From
Non-small Cell Lung Cancer Therapeutics Market - Global Forecast 2026-2032 - Product Image

Non-small Cell Lung Cancer Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 195 Pages
  • Global
From
Extensive Stage Small Cell Lung Cancer Market - Global Forecast 2026-2032 - Product Image

Extensive Stage Small Cell Lung Cancer Market - Global Forecast 2026-2032

  • Report
  • 195 Pages
  • Global
From
Non-Small Cell Lung Cancer (NSCLC) Therapeutics - Global Strategic Business Report - Product Image

Non-Small Cell Lung Cancer (NSCLC) Therapeutics - Global Strategic Business Report

  • Report
  • 271 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.